SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that an abstract related to comprehensive results from the company's Phase 2b ALPINE4 trial of aldafermin in patients with compensated cirrhosis (liver fibrosis stage 4, or, F4) due to nonalcoholic steatohepatitis (NASH) has been selected for an oral plenary presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, which will take place November 10-14, 2023, in Boston, MA.
Oral Presentation at AASLD The Liver Meeting
Title: | Positive results from the ALPINE 4 study: a randomized, double-blind, placebo-controlled, multicenter, Phase 2b trial evaluating multiple doses of the FGF19 analogue aldafermin in patients with ... |